Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Head and Neck Neoplasms 3Prostatic Neoplasms 2Mouth Neoplasms 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Oligodendroglioma 1Neuroblastoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 37Radiotherapy 20Bevacizumab 14Carboplatin 10Magnetic Resonance Spectroscopy 9Carmustine 9antineoplaston AS 2-1 8antineoplaston A10 8Irinotecan 8Filgrastim 7Cyclophosphamide 6Cisplatin 6Etoposide 5sargramostim 4Vincristine 4Thiotepa 4Surgical Procedures, Operative 4Specimen Handling 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Everolimus 4Chemotherapy, Adjuvant 4trametinib 3aldesleukin 3Topotecan 3Thalidomide 3Tamoxifen 3Sunitinib 3Procarbazine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Astrocytoma × Fenretinide × Clear all
NCT00006080 2018-06-27

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
CNS

Astrocytoma, Brain Neoplasms, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡